Publikationen

Nissen MJ et al: “The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.” Arthritis Rheumatol. 2016 Sep;68(9):2141-50. doi: 10.1002/art.39691.

Courvoisier DS and Finckh A et al. “Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study.” EBioMedicine. 2016 Sep;11:302-306. doi: 10.1016/j.ebiom.2016.08.024.

Gottenberg JE and Finckh A et al., "Brief Report: Association of Rheumatoid Factor and Anti-Citrullinated Protein Antibody Positivity With Better Effectiveness of Abatacept: Results From the Pan-European Registry Analysis", Arthritis Rheumatology 2016, 68(6): 1346-52.

Mercer LK and Finckh A et al., "Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 Eurpean biologics registers", Ann Rheum Dis 2016 [Epub ahead of print].

Katerina Chatzidionysiou, Cem Gabay et al, “Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration” Arthritis Res Ther. 2016; 18: 50. Published online 2016 Feb 16.

Adrian Ciurea et al., "Does the reason for discontinuation of a firt TNF inhibitor influence the effectiveness of a second TNF inhibitor in axial spondyloarthritis? Results from the Swiss Clinical Quality Management Cohort", Arthritis Research & Therapy 2016, 18:71.

Axel Finckh et al., "The impact of patient heterogeneity and socio-economic factors across nine European countries on abatacept retention in rheumatoid arthritis". RMD Open. 2015 Apr 30;1(1): PMID: 26509062.